-
Clinical and economic outcomes of assigning percutaneous coronary intervention patients to contrast-sparing strategies based on the predicted risk of contrast-induced acute kidney injury J. Med. Econ. (IF 2.4) Pub Date : 2024-04-22 Robert I. Griffiths, Aparna Bhave, Alysha M. McGovern, Liesl M. Hargens, Craig A. Solid, Amit P. Amin
Contrast-sparing strategies have been developed for percutaneous coronary intervention (PCI) patients at increased risk of contrast-induced acute kidney injury (CI-AKI), and numerous CI-AKI risk pr...
-
Impact of pseudomonas aeruginosa on resource utilization and costs in patients with exacerbated non-cystic fibrosis bronchiectasis J. Med. Econ. (IF 2.4) Pub Date : 2024-04-22 Meg Franklin, Michael E Minshall, Federica Pontenani, Sunjay Devarajan
Aims Non‐cystic fibrosis bronchiectasis (NCFB) is a chronic progressive respiratory disorder occurring at a rate ranging from 4.2 to 278.1 cases per 100,000 persons, depending on age, in the United...
-
Healthcare resource utilization and associated costs in patients with metastatic urothelial carcinoma: a real-world analysis using German claims data J. Med. Econ. (IF 2.4) Pub Date : 2024-04-19 Günter Niegisch, Marc-Oliver Grimm, Fraence Hardtstock, Julia Krieger, Alexandra Starry, Ulrike Osowski, Barthold Deiters, Ulf Maywald, Thomas Wilke, Mairead Kearney
This retrospective claims data study characterized real-world treatment patterns, healthcare resource utilization (HCRU), and costs in patients with metastatic urothelial carcinoma (mUC) in Germany...
-
Cost-effectiveness and impact on infections and associated antimicrobial resistance of 20-valent pneumococcal conjugate vaccine in US children previously immunized with PCV13 J. Med. Econ. (IF 2.4) Pub Date : 2024-04-19 Mark H. Rozenbaum, Liping Huang, Alejandro Cane, Adriano Arguedas, Ruth Chapman, Desmond Dillon-Murphy, Maria J. Tort, Vincenza Snow, Erica Chilson, Raymond Farkouh
The US Food and Drug Administration approved the 20-valent pneumococcal conjugate vaccine (PCV20) to prevent pneumococcal disease. In the context of routine PCV20 vaccination, we evaluated the cost...
-
The indirect costs of human papillomavirus-related cancer in Central and Eastern Europe: years of life lost and productivity costs J. Med. Econ. (IF 2.4) Pub Date : 2024-04-19 Ugne Sabale, Eugenia Karamousouli, Lazar Popovic, Zoárd Tibor Krasznai, Daniel Harrop, Anne Meiwald, Robert Hughes, Georgie Weston, Goran Bencina
BACKGROUND:Human papilloma virus (HPV) is a common cause of several types of cancer, including head and neck (oral cavity, pharynx, oropharynx, hypopharynx, nasopharynx, and larynx), cervical, vulv...
-
Statement of Retraction: Hospitalization-related costs associated with oral agents targeting the prostacyclin pathway for pulmonary arterial hypertension J. Med. Econ. (IF 2.4) Pub Date : 2024-04-18
Published in Journal of Medical Economics (Vol. 27, No. 1, 2024)
-
Indirect comparisons of relative efficacy estimates of zuranolone and selective serotonin reuptake inhibitors for postpartum depression J. Med. Econ. (IF 2.4) Pub Date : 2024-04-15 Samantha Meltzer-Brody, Margaret E. Gerbasi, Catherine Mak, Youssef Toubouti, Sarah Smith, Neil Roskell, Robin Tan, Shih-Yin (Sharon) Chen, Kristina M. Deligiannidis
Estimate relative efficacy of zuranolone, a novel oral, Food and Drug Administration-approved treatment for postpartum depression (PPD) in adults vs. selective serotonin reuptake inhibitors (SSRIs)...
-
Validity and measurement equivalence of EQ-5D-5L questionnaire among heart failure patients in Malaysia: a cohort study J. Med. Econ. (IF 2.4) Pub Date : 2024-04-13 Wai Chee Kuan, Kok Han Chee, Sazzli Kasim, Ka Keat Lim, Juman Abdulelah Dujaili, Kenneth Kwing-Chin Lee, Siew Li Teoh
This study aimed to examine the validity of EQ-5D-5L among HFrEF patients in Malaysia, and to explore the measurement equivalence of three main language versions.We surveyed HFrEF patients from two...
-
Addendum J. Med. Econ. (IF 2.4) Pub Date : 2024-04-12
Published in Journal of Medical Economics (Vol. 27, No. 1, 2024)
-
Exploring kidney dialysis costs in the United States: a scoping review J. Med. Econ. (IF 2.4) Pub Date : 2024-04-12 Fiona Stewart, Kristin Kistler, Yuxian Du, Rakesh R. Singh, Bonnie B. Dean, Sheldon X. Kong
The increasing prevalence of end-stage renal disease (ESRD) in the United States (US) represents a considerable economic burden due to the high cost of dialysis treatment. This review examines data...
-
Costs associated with adverse events during treatment episodes for adult attention-deficit/hyperactivity disorder J. Med. Econ. (IF 2.4) Pub Date : 2024-04-11 Jeff Schein, Martin Cloutier, Rebecca Bungay, Marjolaine Gauthier-Loiselle, Ann Childress
Aims: Attention-deficit/hyperactivity disorder (ADHD) medication is frequently associated with adverse events (AEs), but limited real-world data exist regarding their costs from a payer’s perspecti...
-
Comparative adherence of macitentan versus ambrisentan and bosentan in Australian patients with pulmonary arterial hypertension: a retrospective real-world database study J. Med. Econ. (IF 2.4) Pub Date : 2024-04-10 Edmund Lau, Eugene Kotlyar, Yogeshwar Makanji, Dae Young Yu, Jin Yu Tan, Jeremy Casorso, Mahsa H. Kouhkamari, Sooyeol Lim, David Bin-Chia Wu, Paul Bloomfield
Bosentan, ambrisentan, and macitentan are endothelin receptor antagonists (ERAs), currently available in Australia for treatment of pulmonary arterial hypertension (PAH). This study assessed the co...
-
Correction J. Med. Econ. (IF 2.4) Pub Date : 2024-04-10
Published in Journal of Medical Economics (Vol. 27, No. 1, 2024)
-
Cost-effectiveness analysis of minimally invasive surgical treatments for benign prostatic hyperplasia: implications for Japan’s public healthcare system J. Med. Econ. (IF 2.4) Pub Date : 2024-04-08 Hisataka Anezaki, Fumiyasu Endo, Georgia Swan, Kenta Takashima, Sirikan Rojanasarot
Benign prostatic hyperplasia (BPH) represents a significant public health issue in Japan. This study evaluated the lifetime cost-effectiveness of water vapor energy therapy (WAVE) versus prostatic ...
-
Cost effectiveness of implantable cardioverter defibrillators for 1.5 primary prevention of sudden cardiac arrest in China: an analysis from the Improve SCA study J. Med. Econ. (IF 2.4) Pub Date : 2024-04-08 Hui Sun, Xin Liu, Jin Fu, Yin Song, Xiaoxiao Qin, Haiyin Wang
Implantable cardioverter defibrillator (ICDs) for primary prevention (PP) of sudden cardiac arrest (SCA) is underutilized in developing countries. The Improve SCA study has identified a subset of 1...
-
Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK J. Med. Econ. (IF 2.4) Pub Date : 2024-04-09 Karissa Johnston, Lauren C Powell, Evan Popoff, Gil J L’Italien, Robert Pawinski, Aideen Ahern, Sam Large, Thang Tran, Aaron Jenkins
Migraine is the most common disabling headache disorder and is characterized by recurrent throbbing head pain and symptoms of photophobia, phonophobia, nausea, and vomiting. Rimegepant 75mg, an ora...
-
Economic impact analysis of a minimally invasive temperature-controlled radiofrequency device versus nasal surgery for the treatment of nasal airway obstruction in the United States J. Med. Econ. (IF 2.4) Pub Date : 2024-04-05 Michael Yong, Desiree Hollemon, Julie Baxter, Alex Hirst, Sam Bryning, Aimee Fox, Greg Smith, Robert Hughes, Giulia Brandolini, Scott Wolf, Randall Ow
Objective: To determine the economic impact of a minimally invasive temperature-controlled radiofrequency (TCRF) device for treating nasal airway obstruction (NAO).Methods: A budget impact model wa...
-
Assessing the economics of biologic and small molecule therapies for the treatment of moderate to severe ulcerative colitis in Japan: a cost per responder analysis of upadacitinib J. Med. Econ. (IF 2.4) Pub Date : 2024-04-05 Masayuki Saruta, Isao Kawaguchi, Yuji Ogawa, Yuri Sanchez Gonzalez, Naoki Numajiri, Xiaohe Tang, Russell Miller
Patients with moderately to severely active ulcerative colitis have an increasing number of advanced therapy options including several biologics and Janus kinase inhibitors. Though data on efficacy...
-
Quantifying preferences for urea cycle disorder treatments using a discrete choice experiment J. Med. Econ. (IF 2.4) Pub Date : 2024-03-31 Josiah Edelblut, Jeffrey R. Skaar, John Hilton, Matthew Seibt, Kyle Martin, Nandini Hadker, Adrian Quartel, Robert D. Steiner
Urea cycle disorders (UCDs) can cause ammonia accumulation and central nervous system toxicity. Nitrogen-binding medications can be efficacious, but certain attributes may negatively impact adheren...
-
Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective J. Med. Econ. (IF 2.4) Pub Date : 2024-04-04 Thor-Henrik Brodtkorb, Christopher Knight, Farzam Kamgar, Siguroli Teitsson, Murat Kurt, Miraj Y. Patel, Tayla Poretta, Ronac Mamtani, Stephen Palmer
To evaluate the cost-effectiveness of adjuvant nivolumab compared with surveillance for the treatment of patients with high-risk muscle-invasive urothelial carcinoma (MIUC) after radical resection ...
-
The cost-effectiveness of zuranolone versus selective serotonin reuptake inhibitors for the treatment of postpartum depression in the United States J. Med. Econ. (IF 2.4) Pub Date : 2024-03-31 Lasair O’Callaghan, Elizabeth Chertavian, Scott J. Johnson, Erin Ferries, Kristina M. Deligiannidis
The objective of this research is to evaluate the cost-effectiveness of zuranolone, the first oral treatment indicated for postpartum depression (PPD) in adults approved by the United States Food a...
-
Addendum J. Med. Econ. (IF 2.4) Pub Date : 2024-04-02
Published in Journal of Medical Economics (Vol. 27, No. 1, 2024)
-
Value of next generation sequencing (NGS) testing in advanced cancer patients J. Med. Econ. (IF 2.4) Pub Date : 2024-04-02 Jesse D. Ortendahl, Gebra Cuyun Carter, Snehal G. Thakkar, Katalin Bognar, David W. Hall, Yara Abdou
The availability of targeted therapies for oncology patients is increasing. Available genomic tests to identify treatment-eligible patients include single gene tests and gene panel tests, including...
-
Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo J. Med. Econ. (IF 2.4) Pub Date : 2024-03-25 Siguroli Teitsson, Thor-Henrik Brodtkorb, Murat Kurt, Miraj Y. Patel, Tayla Poretta, Christopher Knight, Farzam Kamgar, Stephen Palmer
To present alternative approaches related to both structural assumptions and data sources for the development of a decision analytic model for evaluating the cost-effectiveness of adjuvant nivoluma...
-
Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden J. Med. Econ. (IF 2.4) Pub Date : 2024-03-26 Lewis Ralph, Kate Young, Navneet Upadhyay, Vimalanand Shrikant Prabhu, Christina Ljungcrantz, Rachid Massaad, Ruifeng Xu, Anna Giertz, Adil Merchant, Robert Orlowski, Linda Duska
Pembrolizumab plus lenvatinib was recently approved for the treatment of advanced or recurrent endometrial carcinoma in women with disease progression on or following prior treatment with a platinu...
-
The burden of end-stage renal disease in Khartoum, Sudan: cost of illness study J. Med. Econ. (IF 2.4) Pub Date : 2024-03-17 Hiba Ali Hajomer, Osama Ahmed Elkhidir, Shaima Omer Elawad, Ola Hatim Elniema, Mustafa Khalid Khalid, Lina S. Altayib, Ibrahim Ahmed Abdalla, Tahani Amin Mahmoud
The incidence of end-stage renal disease (ESRD) in Sudan is increasing, affecting the economic status of patients, caregivers and society. This study aimed to measure ESRD’s costs, including direct...
-
Post-approval indications and clinical trials for cardiovascular drugs: some implications of the US Inflation Reduction Act J. Med. Econ. (IF 2.4) Pub Date : 2024-03-18 Henry Grabowski, Genia Long
To describe the historical baseline landscape of cardiovascular drug post-approval activity, including the number and timing of post-approval clinical trials and approved indications. The US Inflat...
-
Placebo responses vary by route of administration in migraine prevention trials. What does this mean? J. Med. Econ. (IF 2.4) Pub Date : 2024-03-12 Christina I. Deligianni, Paolo Martelletti, Dimos D. Mitsikostas
Published in Journal of Medical Economics (Vol. 27, No. 1, 2024)
-
A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands J. Med. Econ. (IF 2.4) Pub Date : 2024-03-12 Martijn J. H. G. Simons, Peter M. Machielsen, Jelle A. Spoorendonk, Tim Ignacio, Pieter B. Drost, Tim Jacobs, Felix E. de Jongh
Patients with early-stage hormone receptor positive, human epidermal growth factor receptor-2 (HER2) negative invasive breast cancer with 1–3 positive lymph nodes (N1) often undergo surgical excisi...
-
Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma J. Med. Econ. (IF 2.4) Pub Date : 2024-03-15 Karen MacDonald, Marc Pondel, Ivo Abraham
Aims: To estimate, in the setting of recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) for an assumed 1,207 incident US cases in 2024, (1) the cost-efficiency of a toripalimab-gemcitabine-...
-
A cost-consequence analysis of the Xpert Xpress CoV-2/Flu/RSV plus test strategy for the diagnosis of influenza-like illnesses J. Med. Econ. (IF 2.4) Pub Date : 2024-03-11 Shawn Davies, Emily Boller, Jordan Chase, Anne Beaubrun, Cynthia Miller, Ivar Jensen
Influenza-like illnesses (ILI) affect millions each year in the United States (US). Determining definitively the cause of symptoms is important for patient management. Xpert Xpress CoV-2/Flu/RSV pl...
-
Value-based pricing: a potential solution to difficult pricing discussions and payers’ negotiations J. Med. Econ. (IF 2.4) Pub Date : 2024-03-11 G. Tremblay, A. Poirier, L. Monfort
Published in Journal of Medical Economics (Vol. 27, No. 1, 2024)
-
Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England J. Med. Econ. (IF 2.4) Pub Date : 2024-03-11 Tariq H. Iqbal, Nicholas Kennedy, Anjan Dhar, Waqas Ahmed, Richard F. Pollock
Anemia is the most common extraintestinal complication of inflammatory bowel disease (IBD), with approximately half of cases caused by iron deficiency (ID). Intravenous iron is the preferred ID ane...
-
Eliciting health state utilities in Japanese diabetic and obese patients through the time trade-off method. Does the conjecture fat and happy stand true? J. Med. Econ. (IF 2.4) Pub Date : 2024-03-11 Panagiotis Petrou
Published in Journal of Medical Economics (Vol. 27, No. 1, 2024)
-
Treatment patterns and healthcare resource utilization in patients with metastatic hormone-sensitive prostate cancer and nonmetastatic castration-resistant prostate cancer in China: a real-world observational study J. Med. Econ. (IF 2.4) Pub Date : 2024-03-11 Yong Wang, Chunxiao Liu, Chuan Liu, Yongji Lu, Lu Ban, Yuanjie Niu
This study assessed the treatment patterns, healthcare resource utilization (HRU), costs, and annual prevalence and incidence of metastatic hormone-sensitive prostate cancer (mHSPC) and nonmetastat...
-
Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States J. Med. Econ. (IF 2.4) Pub Date : 2024-03-11 Deborah R. Kaye, Ibrahim Khilfeh, Erik Muser, Laura Morrison, Frederic Kinkead, Patrick Lefebvre, Dominic Pilon, Daniel George
To describe healthcare resource utilization (HRU) and costs of patients with metastatic castration-sensitive prostate cancer (mCSPC).Linked data from Flatiron Metastatic PC Core Registry and Komodo...
-
Budget impact analysis for three glucagon-like peptide-1 receptor agonist-based therapies for type 2 diabetes mellitus management in Saudi Arabia J. Med. Econ. (IF 2.4) Pub Date : 2024-03-11 Hussain A. Al-Omar, Hind S. Almodaimegh, Abubker Omaer, Lamya M. Alzubaidi, Bandar Al-Harbi, Ibtisam Al-Harbi, Mohamed Hassan, Omar Akhtar
This study presents a budget impact analysis (BIA) conducted in Saudi Arabia, evaluating the cost implications of adopting semaglutide, tirzepatide, or dulaglutide in the management of type 2 diabe...
-
Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes J. Med. Econ. (IF 2.4) Pub Date : 2024-03-11 Dina Abushanab, Salma Chbib, Rasha Kaddoura, Moza Al Hail, Palli Valappila Abdul Rouf, Wessam El Kassem, Jassim Shah, Ramesh Kumar Ravindran Nair, Daoud Al-Badriyeh
To evaluate the cost-effectiveness of dapagliflozin added to standard of care (SoC) versus SoC in heart failure with reduced ejection fraction (HFrEF) and without type 2 diabetes mellitus (T2DM) pa...
-
Health state utilities associated with weight loss: preferences of people with type 2 diabetes and obesity in Japan J. Med. Econ. (IF 2.4) Pub Date : 2024-03-11 Louis S. Matza, Katie D. Stewart, Josefine Redig, Timothy A. Howell, Walter Morris, Rachel S. Newson, Alexander Yasui, Jack Ishak, Kristina S. Boye
Health state utilities associated with weight change are needed for cost-utility analyses (CUAs) examining the value of treatments for type 2 diabetes and obesity. Previous studies have estimated t...
-
Integrated budget impact model to estimate the impact of introducing selpercatinib as a tumor-agnostic treatment option for patients with RET-altered solid tumors in the US J. Med. Econ. (IF 2.4) Pub Date : 2024-03-06 Naleen Raj Bhandari, Adrienne M. Gilligan, Julie Myers, Amine Ale-Ali, Lee Smolen
To estimate the potential budget impact on US third party payers (commercial or Medicare) associated with addition of selpercatinib as a tumor-agnostic treatment for patients with Rearranged during...
-
A matching-adjusted indirect comparison of results from REDUCE and RESPECT—two randomized trials on patent foramen ovale closure devices to prevent recurrent cryptogenic stroke J. Med. Econ. (IF 2.4) Pub Date : 2024-02-29 Scott E. Kasner, Lars Sondergaard, Mitesh Nakum, Melissa Gomez Montero, Mahmoud Hashim, Erik J. Landaas
Two randomized clinical trials, REDUCE and RESPECT, demonstrated that patent foramen ovale (PFO) closure in combination with antithrombotic therapy was more effective for the prevention of recurren...
-
Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer J. Med. Econ. (IF 2.4) Pub Date : 2024-02-24 Christine M. Bestvina, Dexter Waters, Laura Morrison, Bruno Emond, Marie-Hélène Lafeuille, Annalise Hilts, Patrick Lefebvre, Andy He, Julie Vanderpoel
To assess US payers’ per-patient cost of testing associated with next-generation sequencing (NGS) versus polymerase chain reaction (PCR) biomarker testing strategies among patients with metastatic ...
-
Economic burden of COVID-19 for employers and employees in the United States J. Med. Econ. (IF 2.4) Pub Date : 2024-02-24 Heather Sell, Kassandra Schaible, Julie A. Gouveia-Pisano, Alon Yehoshua, Deepa Malhotra, Manuela Di Fusco, Ashley S. Cha-Silva, Kathleen M. Andersen, Lance Nicholls, Suzanne N. Landi, Catherine Rolland, Jennifer Judy
Describe the economic burden of COVID-19 on employers and employees in the United States (US).A targeted literature review was conducted to evaluate the impact of COVID-19 on US-based employers and...
-
The economic burden of Ebola virus disease: a review and recommendations for analysis J. Med. Econ. (IF 2.4) Pub Date : 2024-02-23 Mavis Obeng-Kusi, Jennifer Martin, Ivo Abraham
Ebola virus disease (EVD) continues to be a major public health threat globally, particularly in the low-and-middle-income countries (LMICs) of Africa. The social and economic burdens of EVD are su...
-
Economic burden and secondary complications of influenza-related hospitalization among adults in the US: a retrospective cohort study J. Med. Econ. (IF 2.4) Pub Date : 2024-02-22 Tianyan Hu, Amanda C. Miles, Taryn Pond, Constantina Boikos, Farzaneh Maleki, Tamuno Alfred, Santiago M. C. Lopez, Leah McGrath
This study aims to describe the healthcare resource utilization (HCRU) and direct medical cost of influenza-related hospitalizations to illustrate the persistent economic burden of influenza among ...
-
Insights into artificial intelligence utilisation in drug discovery J. Med. Econ. (IF 2.4) Pub Date : 2024-02-22 Abdallah Abou Hajal, Ahmad Z. Al Meslamani
Published in Journal of Medical Economics (Vol. 27, No. 1, 2024)
-
Correction J. Med. Econ. (IF 2.4) Pub Date : 2024-02-20
Published in Journal of Medical Economics (Vol. 27, No. 1, 2024)
-
Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK J. Med. Econ. (IF 2.4) Pub Date : 2024-02-19 Grant McCarthy, Kate Young, Matthew Madin-Warburton, Tyler Mantaian, Elizabeth Brook, Kaylie Metcalfe, Jan Mikelson, Ruifeng Xu, Carl Seyla-Hammer, Raquel Aguiar-Ibáñez, Mayur Amonkar
Patients with previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) tumours have limited chemotherapeutic treatment options. Pembrolizumab received approval fr...
-
Cost-effectiveness analysis of sodium zirconium cyclosilicate for hyperkalemia among patients with chronic kidney disease or heart failure in Kuwait J. Med. Econ. (IF 2.4) Pub Date : 2024-02-14 Gihan Hamdy Elsisi, Mohamed M. Ibrahim Mahmoud, Khaldoon Al-Humood, Anas Al-Yousef
Our model was conducted from Kuwaiti payer’s perspective to provide evidence on the cost-effectiveness of Sodium zirconium cyclosilicate (SZC) versus patiromer to correct and maintain serum potassi...
-
Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by EGFR mutation type J. Med. Econ. (IF 2.4) Pub Date : 2024-02-13 Pratyusha Vadagam, Dexter Waters, Inyoung Lee, Justin Chen, Dajun Tian, Aimee M. Near, Derek Lyle, Julie Vanderpoel
This study described treatment patterns, healthcare resource utilization (HRU) and costs among advanced or metastatic non-small cell lung cancer (a/mNSCLC) patients with different epidermal growth ...
-
Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results J. Med. Econ. (IF 2.4) Pub Date : 2024-02-13 Olalekan O. Oluwole, Markqayne D. Ray, Neil Davies, Rory Bradford, Calum Jones, Anik R. Patel, Frederick L. Locke
To provide an update on the cost-effectiveness of the chimeric antigen receptor (CAR) T-cell therapies axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for the treatment of relapse...
-
Reduced mortality, complications, and economic burden among medicare beneficiaries receiving influenza antivirals J. Med. Econ. (IF 2.4) Pub Date : 2024-02-13 Jennie H. Best, Sheila R. Reddy, Eunice Chang, Katalin Bognar, Marian H. Tarbox, Steven E. Cagas, Arpamas Seetasith
Antiviral therapy may be underutilized in patients at high risk for increased clinical and economic burden (e.g. older adults). We aimed to examine the benefits associated with antiviral treatment ...
-
Challenges in health economics research: insights from real-world examples J. Med. Econ. (IF 2.4) Pub Date : 2024-02-06 Ahmad Z. Al Meslamani
Published in Journal of Medical Economics (Vol. 27, No. 1, 2024)
-
Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation J. Med. Econ. (IF 2.4) Pub Date : 2024-02-02 Deborah R. Kaye, Ibrahim Khilfeh, Erik Muser, Laura Morrison, Frederic Kinkead, Ana Urosevic, Patrick Lefebvre, Dominic Pilon, Daniel J. George
To describe healthcare costs of patients with metastatic castration-resistant prostate cancer (mCRPC) initiating first-line (1 L) therapies from a US payer perspective.Patients initiating a Flatiro...
-
A cost-effectiveness analysis of intrauterine spacers used to prevent the formation of intrauterine adhesions following endometrial cavity surgery J. Med. Econ. (IF 2.4) Pub Date : 2024-01-30 Luke Schmerold, Coby Martin, Aashay Mehta, Dhruv Sobti, Ajit Kumar Jaiswal, Jatinder Kumar, Ian Feldberg, Malcolm G. Munro, Won Chan Lee
To assess, from a United States (US) payer’s perspective, the cost-effectiveness of gels designed to separate the endometrial surfaces (intrauterine spacers) placed following intrauterine surgery.A...
-
Validation of overall survival extrapolations made by TLV in the assessment of cost-effectiveness of oncology drugs in Sweden – A pilot study comparing extrapolated and observed life-years gained J. Med. Econ. (IF 2.4) Pub Date : 2024-01-29 Jonas Björnerstedt, Hannah Almqvist, Douglas Lundin, Niklas Zethraeus
The aim of the study is to assess the accuracy of overall survival (OS) extrapolations in cost-effectiveness analysis made by the Dental and Pharmaceutical Benefits Agency (TLV) to decide on the re...
-
Impact of Ebola epidemics on the daily operation of existing systems in Eastern Democratic Republic of the Congo: a brief review J. Med. Econ. (IF 2.4) Pub Date : 2024-01-22 Daniel Mukadi-Bamuleka, Antoine Nkuba-Ndaye, Placide Mbala-Kingebeni, Steve Ahuka-Mundeke, Jean-Jacques Muyembe-Tamfum
to provide insights into the recent Ebola virus disease (EVD) outbreaks on different aspects of daily life in the Democratic Republic of the Congo and propose possible solutions.We collected inform...
-
Why are digital health policies crucial? J. Med. Econ. (IF 2.4) Pub Date : 2024-01-18 Ahmad Z. Al Meslamani
Published in Journal of Medical Economics (Vol. 27, No. 1, 2024)
-
Correction J. Med. Econ. (IF 2.4) Pub Date : 2024-01-10
Published in Journal of Medical Economics (Vol. 27, No. 1, 2024)
-
Correction J. Med. Econ. (IF 2.4) Pub Date : 2024-01-13
Published in Journal of Medical Economics (Vol. 27, No. 1, 2024)